DLBCL

Videos

Loncastuximab Teserine Plus Ibrutinib Shows Encouraging Anti-Tumor Activity in Patients With R/R DLBCL

12/15/2021

Carmelo Carlo-Stella, MD, discusses a phase 2 study on loncastuximab tesirine plus ibrutinib for patients with advanced DLBCL. These data were presented at the 2021 ASH Annual Meeting.

Carmelo Carlo-Stella, MD,...

12/15/2021

Oncology

News

Naratuximab Emtansine Plus Rituximab Shows Safety in Patients With DLBCL and Other B-NHLs

12/08/2021

A phase 2 study of naratuximab emtansine plus rituximab found it has promising safety and efficacy for patients with DLBCL and other B-NHLs; these data were presented at the 2021 Annual ASH Meeting.

A phase 2 study of naratuximab...

12/08/2021

Oncology

Test Your Knowledge

Quiz: Is This Acalabrutinib Combo Safe for Patients With R/R DLBCL?

11/15/2021

True or false: Acalabrutinib plus AXD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy.

True or false: Acalabrutinib...

11/15/2021

Oncology

News

BTK, STAT3 Targeting Is Safe in R/R DLBCL, But Has Limited Efficacy

11/15/2021

A phase 1b study found acalabrutinib, plus AZD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy; these findings were presented at the 2021 ASH Annual Meeting.

A phase 1b study found...

11/15/2021

Oncology

Test Your Knowledge

Quiz: Does Tafasitamab Show Tolerability in DLBCL?

11/11/2021

True or false: Tafasitamab with or without lenalidomide and R-CHOP are both tolerable regimens for patients with DLBCL.

True or false: Tafasitamab with...

11/11/2021

Oncology

Conference Insider

Tafasitamab With or Without Lenalidomide and R-CHOP Tolerable for Patients With DLBCL

11/11/2021

A phase 1B study shared at the 2021 Annual ASH Meeting reported on the safety and tolerability of tafasitamab in newly diagnosed DLBCL.

A phase 1B study shared at the...

11/11/2021

Oncology

Test Your Knowledge

Quiz: What Combo Regimen Shows a Promising Safety Profile in DLBCL?

11/09/2021

Which of the following combinations showed a promising safety profile in patients with DLBCL and other B-NHLs?

Which of the following...

11/09/2021

Oncology

Test Your Knowledge

Quiz: Is Glofitamab Plus R-CHOP Tolerable for Patients With NHL, DLBCL?

11/08/2021

True or false: Glofitamab plus R-CHOP has tolerable safety in R/R NHL and previously untreated DLBCL?

True or false: Glofitamab plus...

11/08/2021

Oncology

News

Glofitamab Plus R-CHOP Induces High Response Rates in NHL, DLBCL

11/08/2021

Findings from a phase 1b study found glofitamab plus R-CHOP induces high response rates with minimal CRS in patients with R/R NHL and previously untreated DLBCL. These data were presented at the 2021 ASH Annual Meeting.

Findings from a phase 1b study...

11/08/2021

Oncology

Conference Insider

Long-Lasting Remission With Dual Targeting CAR-T Therapy for R/R DLBCL

12/15/2020

Patients with relapsed/refractory DLBCL given AUTO3 (a CD19/22 dual targeting CAR-T therapy) plus pembrolizumab had durable responses.

Patients with...

12/15/2020

Oncology